Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2
Nicola J. Mason(University of Pennsylvania), Amy K. LeBlanc(National Cancer Institute), Anthony J. Mutsaers(University of Guelph), Cheryl A. London(The Ohio State University), Valerie MacDonald‐Dickinson(University of Saskatchewan), Kristen Weishaar(Colorado State University), J. Matthew Mahoney(University of Pennsylvania), Paul R. Hess(North Carolina State University), Heather Wilson‐Robles(NanoSD (United States)), William C. Kisseberth(The Ohio State University), Cheryl E. Balkman(Cornell University), J. Paul Woods(University of Guelph), Raelene M. Wouda(Services Australia), David M. Vail(University of Wisconsin–Madison), Audrey Ruple(Virginia Tech), Laura E. Selmic(The Ohio State University), Haley Leeper(Oregon State University), Jennifer L. Willcox(University of California, Davis), Antonia Rotolo(University of Pennsylvania), Jenna H. Burton(University of California, Davis), Sushant Patkar(National Institutes of Health), Mary Lynn Higginbotham(Kansas State University), Angela L. McCleary‐Wheeler(Cornell University), Corey Saba(University of Georgia), Lisa G. Barber(Tufts University), Jeffrey N. Bryan(Missouri College), Christina Mazcko(National Institutes of Health), Brian K. Flesner(Missouri College)
Cited by 10
Related Papers
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
|Nature Communications|2020|156
Characterization of STAT3 activation and expression in canine and human osteosarcoma
|BMC Cancer|2009|114